Previous 10 | Next 10 |
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver ...
Esperion Therapeutics (ESPR) has appointed Sheldon Koenig as COO, effective today. Tim M. Mayleben, President and CEO said, “Sheldon is the right leader at the right time to navigate our company through the opportunities that lie ahead of us as we continue a period of rapid g...
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M. Mayleben, president and chief execu...
Esperion ([[ESPR]] +3.6%) announces pooled data from four of Phase 3 studies evaluating Nexletol (bempedoic acid) as an adjunct to diet for lowering LDL-C ("bad" cholesterol) in adults.Data analysis from a subgroup of 580+ patients who cannot tolerate any dose of a statin, show...
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 - - Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and...
Esperion (ESPR) has priced upsized $250M (from $200M) of 4.00% convertible senior unsecured subordinated notes due November 15, 2025 in a private offering.nitial purchasers granted an option to purchase up to an additional $30M of the notes.Closing date is November 16. Interest on the no...
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qu...
Esperion ([[ESPR]] -9.2%) to offer $200M convertible senior subordinated notes due 2025 to institutional buyers. Initial purchasers have an option to purchase up to an additional $30M notes.Conversion price and other terms are yet to be determined.Net proceeds will be used to pay the cos...
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Subordinated Notes due 2025 (the “notes”) in a pr...
Esperion's approved product bempedoic acid is a non-statin, lipid-lowering drug with proven efficacy. However, high burn rate, poor uptake, and coronavirus have all dampened the prospects of the company. The latest earnings call has a lot of aggressive posturing, but does not give...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...